| Feb 27 2025 |
Florida Court Rules That the Florida Constitution Requires Employers to Accommodate Off-Duty Medical Marijuana Use |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Feb 27 2025 |
This Week in 340B: February 18 – 24, 2025 |
McDermott Will & Schulte LLP |
| Feb 26 2025 |
Guiding Your Company Through Trump’s New Latin America Enforcement Policy |
Bracewell LLP |
| Feb 26 2025 |
Backwards Down the Number Line: Assessing the State of Alabama’s Medical Cannabis Program Four Years After Its Enactment |
Bradley Arant Boult Cummings LLP |
| Feb 26 2025 |
FTC COPPA Updates Provide New Protections for Children |
Sheppard, Mullin, Richter & Hampton LLP |
| Feb 26 2025 |
Lawsuit Alleges FDA Has Unduly Delayed Response to PFAS Petition |
Keller and Heckman LLP |
| Feb 26 2025 |
FDA Delays Effective Date for ‘Healthy’ Rule |
Keller and Heckman LLP |
| Feb 25 2025 |
GLP-1 Receptor Agonists: New Frontiers and Challenges |
Foley & Lardner LLP |
| Feb 25 2025 |
Food & Chemicals Unpacked: Making-up for Lost Time: FDA’s Increased Oversight of Cosmetics [Podcast] |
Keller and Heckman LLP |
| Feb 25 2025 |
FDA Bans Red No. 3: What Companies Need to Know |
O'Toole Scrivo, LLC |
| Feb 25 2025 |
GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List |
Foley & Lardner LLP |
| Feb 25 2025 |
A Deepened Divide: Appellate Court Joins False Claims Act Circuit Split in Favor of Health Care Defendants |
Polsinelli PC |
| Feb 25 2025 |
The Story of the Ghost: How a “Loophole” Created a Behemoth of Intoxicating Cannabis Products and What (If Anything) Congress Intends to Do About It |
Bradley Arant Boult Cummings LLP |
| Feb 24 2025 |
Opioids and Common Law Liability for Indirect Economic Harm |
Pierce Atwood LLP |
| Feb 24 2025 |
PFAS Lawsuit Against Industrial Users of PFAS Highlights Risks |
CMBG3 Law |
| Feb 23 2025 |
Multiple States Propose Bans on Food Additives and “Ultra-Processed Foods” |
Keller and Heckman LLP |
| Feb 21 2025 |
FDA Continues Push to Improve Food Labeling Practices in the United States |
Mintz |
| Feb 21 2025 |
McDermott+ Check-Up: February 21, 2025 |
McDermott Will & Schulte LLP |
| Feb 21 2025 |
Navigating the EPR Laws: What Alcohol Beverage Producers Need to Know |
McDermott Will & Schulte LLP |
| Feb 20 2025 |
Make Food “Healthy” Again: FDA’s Resolution for a Healthier 2025 |
Foley & Lardner LLP |
| Feb 20 2025 |
China on the Move: Lessons from China’s 2024 National Negotiation of Drug Prices |
Greenberg Traurig, LLP |
| Feb 20 2025 |
It’s The Hope That Kills You: My Experience with Alabama’s Medical Cannabis Experiment |
Bradley Arant Boult Cummings LLP |
| Feb 19 2025 |
This Week in 340B: February 11 – 17, 2025 |
McDermott Will & Schulte LLP |
| Feb 19 2025 |
Personal Jurisdiction Considerations for International Biosimilars Companies |
Polsinelli PC |
| Feb 19 2025 |
Health Canada Launches FOP Labeling Awareness Initiative |
Keller and Heckman LLP |
| Feb 19 2025 |
Alabama Plans to Issue Medical Cannabis Testing License This Summer |
Bradley Arant Boult Cummings LLP |
| Feb 19 2025 |
President Trump Signs Executive Order Establishing the Make America Healthy Again Commission |
Keller and Heckman LLP |
| Feb 19 2025 |
Health Agencies Face Terminations; Jim Jones Resigns from FDA’s Human Foods Program |
Keller and Heckman LLP |
| Feb 18 2025 |
Effective Dates of DEA Final Rules for Telemedicine Prescribing Delayed |
Epstein Becker & Green, P.C. |
| Feb 18 2025 |
January 2025 Bounty Hunter Plaintiff Claims |
Keller and Heckman LLP |
| Feb 18 2025 |
DEA Delays Final Buprenorphine Rule |
Foley & Lardner LLP |
| Feb 18 2025 |
For Whom the Bell Tolls: Alabama Proposal Would Ban All Psychoactive Hemp |
Bradley Arant Boult Cummings LLP |
| Feb 15 2025 |
Recent Federal Developments for February 14, 2025 |
Bergeson & Campbell, P.C. |
| Feb 14 2025 |
Twenty-Three States Support Iowa Pork Producers Association Petition for SCOTUS Review of Prop 12 |
Keller and Heckman LLP |
| Feb 14 2025 |
Trademark Parody: Sour Patch Kids Sues Cannabis Brand to Protect IP |
Norris McLaughlin P.A. |
